@inbook{433593ac971e4f3a91e7259e6f9a9fbd,
title = "Hodgkin lymphoma and PD-1 blockade",
abstract = "Classical Hodgkin lymphoma (cHL) is characterized by nearly universal genetic alterations at 9p24.1, resulting in increased expression of PD-1 ligands and immune evasion. Disruption of the PD-1 pathway with anti-PD-1 monoclonal antibodies (mAbs) can restore an antitumor immune response in many patients. Based on high overall response rates in cHL patients with relapsed or refractory (R/R) disease, two PD-1 mAbs, nivolumab and pembrolizumab, received accelerated approval in North America and Europe. Currently, numerous ongoing trials are combining PD-1 mAbs with rationally selected agents in the R/R setting and testing PD-1 blockade earlier in the treatment paradigm with potentially curative therapies. These trials and a rapidly improving understanding of mechanisms of immune resistance to PD-1 blockade have the potential to further improve outcomes for patients with cHL.",
keywords = "Immune checkpoint blockade, Immune evasion, Nivolumab, PD-1, PD-L1, PD-L2, Pembrolizumab",
author = "Reid Merryman and Philippe Armand and Stephen Ansell",
note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2020.",
year = "2020",
doi = "10.1007/978-3-030-32482-7_23",
language = "English (US)",
series = "Hematologic Malignancies",
publisher = "Springer",
pages = "395--409",
booktitle = "Hematologic Malignancies",
}